AstraZeneca (AZN)
(Delayed Data from NSDQ)
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
by Zacks Equity Research
Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $66.52, moving +0.41% from the previous trading session.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.
Astrazeneca (AZN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
by Kinjel Shah
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
by Zacks Equity Research
Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
Why the Market Dipped But Astrazeneca (AZN) Gained Today
by Zacks Equity Research
Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Yes Virginia, There Is a Santa Claus Rally
by Mark Vickery
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
by Zacks Equity Research
FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.